Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Bliss GVS Pharma Ltd

BLISSGVS

Bliss GVS Pharma Ltd

BLISSGVS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,308 cr, stock is ranked 1,346
High RiskStock is 3.76x as volatile as Nifty
124.261.98% (-2.51)
124.261.98% (-2.51)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,308 cr, stock is ranked 1,346
High RiskStock is 3.76x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,308 cr, stock is ranked 1,346
High RiskStock is 3.76x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
20.621.300.40%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bliss GVS Pharma Limited is engaged in developing, manufacturing and marketing pharmaceutical formulations.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -3.12%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.43% to 0.21%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -9.41%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue571.24810.94841.18936.20728.50597.43778.94769.38798.98820.36
Raw Materialssubtract262.55368.69391.70618.79435.67341.59420.18374.38390.46681.51
Power & Fuel Costsubtract4.725.585.494.765.888.148.257.1310.43
Employee Costsubtract33.7461.3569.2342.3253.6968.0976.1586.1795.58
Selling & Administrative Expensessubtract67.19117.9087.5749.9645.3044.9180.6580.4585.89
Operating & Other expensessubtract22.9842.1997.7225.1038.837.82117.4886.1366.45
Depreciation/Amortizationsubtract13.2620.1421.388.9412.5917.2317.3318.6726.3827.63
Interest & Other Itemssubtract18.6119.6922.804.417.575.514.7410.366.919.33
Taxes & Other Itemssubtract65.7193.3686.5158.1931.7135.6339.1335.2241.4138.43
EPS8.007.955.7012.009.436.641.456.827.236.06
DPS0.500.601.001.000.500.500.500.500.500.50
Payout ratio0.060.080.180.080.050.080.340.070.070.08
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2019

Annual Report Unavailable

Investor Presentation

May 21PDF
Feb 1PDF
Nov 3PDF
Aug 9PDF
FY 2020

Annual report

PDF

Investor Presentation

Aug 21PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Bliss GVS Pharma Ltd17.341.300.40%
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare BLISSGVS with any stock or ETF
Compare BLISSGVS with any stock or ETF
BLISSGVS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 2.34%

Decreased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.12%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding34.82%0.00%6.56%12.13%46.49%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep16.50%16.31%15.35%14.73%13.25%12.13%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Bliss GVS Pharma Ltd

Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0008%0.07%0.07%87/102 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

BLISSGVS has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.38%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.84 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 18, 2024

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jul 18, 2024

Cash Dividend

Ex DateEx DateJul 12, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jul 12, 2023

Cash Dividend

Ex DateEx DateJun 20, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jun 20, 2022

Cash Dividend

Ex DateEx DateSep 13, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 13, 2021

Cash Dividend

Ex DateEx DateSep 17, 2020

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 17, 2020

News & Opinions
Earnings
Bliss GVS Pharma consolidated net profit declines 42.66% in the September 2024 quarter

Net profit of Bliss GVS Pharma declined 42.66% to Rs 24.26 crore in the quarter ended September 2024 as against Rs 42.31 crore during the previous quarter ended September 2023. Sales rose 2.74% to Rs 217.68 crore in the quarter ended September 2024 as against Rs 211.88 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales217.68211.88 3 OPM %19.0525.66 - PBDT42.6965.52 -35 PBT35.7159.13 -40 NP24.2642.31 -43 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Bliss GVS Pharma to table results

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Bliss GVS Pharma allots 1.57 lakh equity shares under ESOP

Bliss GVS Pharma has allotted 157,550 equity shares under ESOP on 04 October 2024. With this allotment, the paid up equity share capital has increased to 10,53,02,022 equity shares of Re. 1/- each aggregating Rs. 10,53,02,022/-. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bliss GVS Pharma to convene board meeting

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Bliss GVS Pharma declines after Palghar units gets Form 483 with 3 observations from US FDA

1 year agoBusiness Standard

Bliss GVS Pharma share price falls on observations from USFDA

1 year agoMoneycontrol

MRO-TEK Realty Ltd leads gainers in ‘B’ group

1 year agoBusiness Standard

Bliss GVS Pharma reports consolidated net profit of Rs 27.94 crore in the December 2022 quarter

1 year agoBusiness Standard

Bliss GVS Pharma consolidated net profit declines 34.88% in the September 2022 quarter

2 years agoBusiness Standard

Bliss GVS Pharma consolidated net profit rises 6.06% in the June 2022 quarter

2 years agoBusiness Standard